Aterian Plc Regulatory News (ATN)

28 Apr 2005 10:45

28 April 2005Not for release, publication or distribution in, into or from Australia,Canada, Japan or the United States Recommended Offer by UBS Limited on behalf of Microgen plc for AttentiV Systems Group plc Additional Irrevocable Undertaking Further to the announcement released earlier today by Microgen plc ("Microgen")regarding its agreed terms of a recommended offer for the entire issued and tobe issued share capital of AttentiV Systems Group plc ("AttentiV") ("Offer"),Microgen announces that it has since received an irrevocable undertaking fromGartmore Investment Limited ("Gartmore") to accept the Offer in respect of1,535,628 AttentiV shares held by Gartmore, representing approximately 2.5 percent. of AttentiV's existing issued share capital. The irrevocable undertakingprovided by Gartmore will cease to be binding only in the event of anannouncement of a third party offer representing at least a 10 per cent.premium to the value of the Offer.Microgen has now received irrevocable undertakings from AttentiV shareholdersto accept (or use all reasonable endeavours to procure the acceptance of) theOffer in respect of 21,935,757 AttentiV shares, representing approximately 36.2per cent. of AttentiV's existing issued share capital.In addition to the irrevocable undertakings, Microgen has received non-bindingletters of intent to accept the Offer in respect of a total of 9,663,475AttentiV shares representing approximately 16.0 per cent. of the existingissued share capital of Microgen.In aggregate, therefore, Microgen has received irrevocable undertakings andnon-binding letters of intent to accept the Offer in respect of 31,599,232AttentiV shares, representing approximately 52.2 per cent. of the existingissued AttentiV shares.Enquiries:UBS Investment Bank (Financial Adviser to Microgen)John WoollandNick Adams020 7567 8000Financial Dynamics (PR Adviser to Microgen)Giles SandersonBen Way020 7831 3113Hawkpoint (Financial Adviser to AttentiV)Paul BainesGraham Paton020 7665 4500UBS Investment Bank is acting exclusively for Microgen in connection with theOffer and no one else and will not be responsible to anyone other than Microgenfor providing the protections afforded to clients of UBS Investment Bank or forproviding advice in relation to the Offer.Hawkpoint, which is authorised and regulated in the United Kingdom by theFinancial Services Authority, is acting exclusively as financial adviser toAttentiV in connection with the Offer and no one else and will not beresponsible to anyone other than AttentiV for providing the protectionsafforded to clients of Hawkpoint nor for providing advice in relation to theOffer.This announcement does not constitute an offer or invitation to purchase orsubscribe for securities.ENDMICROGEN PLC